Connect
MJA
MJA

Guidelines for the management of acute coronary syndromes 2006

Constantine N Aroney and Philip Aylward
Med J Aust 2007; 187 (6): 372.
Published online: 17 September 2007

In reply: The guidelines were published to provide clinicians with the most contemporary information on the management of acute coronary syndromes based on the international literature, and may include treatments which are not currently available, officially licensed or available through the Pharmaceutical Benefits Scheme in Australia.

  • Constantine N Aroney1
  • Philip Aylward2

  • 1 Holy Spirit Northside Hospital, Brisbane, QLD.
  • 2 Flinders Medical Centre, Adelaide, SA.

Correspondence: 

Competing interests:

We are consultants for, advisory committee members of, or receive honoraria, fees for service, or travel assistance (independent of research-related meetings) from, or have research or other associations with the organisations listed: Constantine Aroney — CSL, Merck Sharpe & Dohme, Sanofi-Aventis; Phil Aylward — Sanofi-Aventis, Pfizer, Merck Sharpe & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Procter & Gamble, Eli Lilly, The Medicines Co, Servier, CSL, Schering Plough.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.